Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl D Kieburtz

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Statistics in Medicine|March 16, 2013
Robust Bayesian inference for multivariate longitudinal data by using normal/independent distributionsSheng Luo, Junsheng Ma, Karl D Kieburtz
Movement Disorders : Official Journal of the Movement Disorder Society|November 2, 2018
Adverse event reporting in clinical trials in Parkinson's Disease: Time for changeC Warren Olanow, Christopher Kenney, Stephen Bandak, et al.
Neurology Open Access|April 15, 2026
Predicting CSF α-Synuclein Seed Amplification Assay Status From Demographics and Clinical DataCharles S Venuto, Konnor Herbst, Lana Chahine, et al.
JAMA Neurology|October 17, 2014
Treating idiopathic intracranial hypertension--replyMichael Wall, Michael P McDermott, Karl D Kieburtz, et al.
The International Journal of Neuroscience|June 28, 2016
Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuationsNeil B Hampson, Karl D Kieburtz, Peter A LeWitt, et al.
Neurology. Clinical Practice|June 24, 2022
Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington DiseaseAndrew McGarry, Peggy Auinger, Karl D Kieburtz, et al.
Clinical Neuropharmacology|January 23, 2023
Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/LevodopaPeter LeWitt, Grace S Liang, C Warren Olanow, et al.
Annals of Clinical and Translational Neurology|July 8, 2016
Predictors of time to initiation of symptomatic therapy in early Parkinson's diseaseTanya Simuni, Jeffrey D Long, Chelsea Caspell-Garcia, et al.
The Lancet. Neurology|July 11, 2014
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trialRobert A Hauser, C Warren Olanow, Karl D Kieburtz, et al.
JAMA Neurology|April 24, 2014
The idiopathic intracranial hypertension treatment trial: clinical profile at baselineMichael Wall, Mark J Kupersmith, Karl D Kieburtz, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Statistics in Medicine|March 16, 2013
Robust Bayesian inference for multivariate longitudinal data by using normal/independent distributionsSheng Luo, Junsheng Ma, Karl D Kieburtz
Movement Disorders : Official Journal of the Movement Disorder Society|November 2, 2018
Adverse event reporting in clinical trials in Parkinson's Disease: Time for changeC Warren Olanow, Christopher Kenney, Stephen Bandak, et al.
Neurology Open Access|April 15, 2026
Predicting CSF α-Synuclein Seed Amplification Assay Status From Demographics and Clinical DataCharles S Venuto, Konnor Herbst, Lana Chahine, et al.
JAMA Neurology|October 17, 2014
Treating idiopathic intracranial hypertension--replyMichael Wall, Michael P McDermott, Karl D Kieburtz, et al.
The International Journal of Neuroscience|June 28, 2016
Prospective evaluation of pulmonary function in Parkinson's disease patients with motor fluctuationsNeil B Hampson, Karl D Kieburtz, Peter A LeWitt, et al.
Neurology. Clinical Practice|June 24, 2022
Suicidality Risk Factors Across the CARE-HD, 2CARE, and CREST-E Clinical Trials in Huntington DiseaseAndrew McGarry, Peggy Auinger, Karl D Kieburtz, et al.
Clinical Neuropharmacology|January 23, 2023
Opicapone Pharmacokinetics and Effects on Catechol- O -Methyltransferase Activity and Levodopa Pharmacokinetics in Patients With Parkinson Disease Receiving Carbidopa/LevodopaPeter LeWitt, Grace S Liang, C Warren Olanow, et al.
Annals of Clinical and Translational Neurology|July 8, 2016
Predictors of time to initiation of symptomatic therapy in early Parkinson's diseaseTanya Simuni, Jeffrey D Long, Chelsea Caspell-Garcia, et al.
The Lancet. Neurology|July 11, 2014
Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trialRobert A Hauser, C Warren Olanow, Karl D Kieburtz, et al.
JAMA Neurology|April 24, 2014
The idiopathic intracranial hypertension treatment trial: clinical profile at baselineMichael Wall, Mark J Kupersmith, Karl D Kieburtz, et al.
Pageof 2